Reducing Hereditary Cancer Act of 2025

Hozzl · 2025-10-08T03:54:38Z

Explore the details of Senate Bill 2760 Reducing Hereditary Cancer Act of 2025 currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

10/8/2025, 3:54 AM

Summary of Bill S 2760

This bill, titled "A bill to amend title XVIII of the Social Security Act," was introduced in the 119th Congress on September 10, 2025. The bill aims to provide hereditary cancer genetic testing for individuals with a history of a hereditary cancer gene mutation in a blood relative or a personal or ancestral history suspicious for hereditary cancer. It also proposes coverage of certain cancer screenings or preventive surgeries for individuals with a germline (inherited) mutation associated with a high risk of developing a preventable cancer.

Congressional Summary of S 2760

Reducing Hereditary Cancer Act of 2025

This bill provides for Medicare coverage of germline mutation testing for individuals with a personal or family history of a hereditary cancer gene mutation or suspected history of hereditary cancer, as well as for associated coverage of risk-reducing surgeries and screenings.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill S 2760

Bill S 2760 is currently in the status of Bill Introduced since September 10, 2025. Bill S 2760 was introduced during Congress 119 and was introduced to the Senate on September 10, 2025. Bill S 2760's most recent activity was Read twice and referred to the Committee on Finance. as of September 10, 2025

Bipartisan Support of Bill S 2760

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill S 2760

Primary Policy Focus

Health

Alternate Title(s) of Bill S 2760

A bill to amend title XVIII of the Social Security Act to provide hereditary cancer genetic testing for individuals with a history of a hereditary cancer gene mutation in a blood relative or a personal or ancestral history suspicious for hereditary cancer, and to provide coverage of certain cancer screenings or preventive surgeries that would reduce the risk for individuals with a germline (inherited) mutation associated with a high risk of developing a preventable cancer.